ulinastatin
Commercial- Indications
- Acute pancreatitis
Company intelligence / Profile preview
Jiangsu Kangyuan Pharmaceutical
Jiangsu Province, Chinaen.kangyuan.com.cn ↗
- Ownership
- Private
- Development stage
- Commercial
01
Overview
Kangyuan Pharmaceutical has a strong base in traditional Chinese medicine and hormone/enzyme APIs. In late 2024 it made a major strategic move by acquiring all equity of the biopharmaceutical R&D company Zhongxin Pharmaceuticals to expand into innovative biologic drugs targeting metabolic diseases such as obesity and diabetes with advanced GLP‑1 fusion protein candidates now entering clinical stages. The company’s main revenue remains traditional medicines but it aims to diversify into high-value biotech innovation.
- Therapeutic areas
- Metabolic DisordersOncologyEndocrinologyHematologyCardiovascular
- Modalities
- Small molecules (e.g. APIs like HCG, HMG, FSH)Recombinant proteins/biologics (via acquisition of Zhongxin Pharma)Fusion proteins (GLP‑1 fusion protein drugs via Zhongxin Pharma)
- Industry
- Biotech
02
Drug pipeline
5 assets4 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Jiangsu Kangyuan Pharmaceutical.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Jiangsu Kangyuan Pharmaceutical.